Tandospirone ophthalmic

Drug Profile

Tandospirone ophthalmic

Alternative Names: AL-8309; AL-8309A; AL-8309B

Latest Information Update: 06 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alcon
  • Class Anxiolytics; Eye disorder therapies; Isoindoles; Piperazines; Pyrimidines
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dry macular degeneration

Most Recent Events

  • 07 Nov 2011 AL 8309B is still in phase III development for geographic atrophy secondary to Age-related macular degeneration in USA
  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 31 Dec 2009 Alcon completes enrolment in its phase III trial for geographic atrophy secondary to Age-related macular degeneration in USA (NCT00890097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top